Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001393905-20-000316
Filing Date
2020-11-09
Accepted
2020-11-09 12:02:58
Documents
52
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT rtsl_10q.htm 10-Q 281026
2 CERTIFICATION rtsl_ex311.htm EX-31.1 6777
3 CERTIFICATION rtsl_ex312.htm EX-31.2 6788
4 CERTIFICATION rtsl_ex321.htm EX-32.1 3456
5 rtsl_ex322.htm EX-32.2 3380
  Complete submission text file 0001393905-20-000316.txt   1529527

Data Files

Seq Description Document Type Size
6 rtsl-20200930.xml EX-101.INS 159329
7 rtsl-20200930.xsd EX-101.SCH 22367
8 rtsl-20200930_cal.xml EX-101.CAL 17922
9 rtsl-20200930_def.xml EX-101.DEF 48603
10 rtsl-20200930_lab.xml EX-101.LAB 125297
11 rtsl-20200930_pre.xml EX-101.PRE 116461
Mailing Address 5580 PETERSON LANE SUITE 200 DALLAS TX 75240
Business Address 5580 PETERSON LANE SUITE 200 DALLAS TX 75240 214-236-1363
Rapid Therapeutic Science Laboratories, Inc. (Filer) CIK: 0001575659 (see all company filings)

EIN.: 462111820 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-55018 | Film No.: 201296753
SIC: 2834 Pharmaceutical Preparations